journal article·2019-12-04Open access

LncRNA SBF2-AS1 promotes the progression of cervical cancer by regulating miR-361-5p/FOXM1 axis

Fangyuan Gao, Jing Feng, Hairong Yao, Yanying Li, Jie Xi, Jun Yang

Abstract

Long non-coding RNAs (lncRNAs) have been identified as critical players in tumorigenesis. Previous studies revealed that lncRNA SBF2-AS1 was involved in tumor progression. However, the role and underlying mechanism of SBF2-AS1 in cervical cancer (CC) remain unknown. In the present study, our data showed that SBF2-AS1 expression was significantly increased in CC. High SBF2-AS1 expression was associated with advanced FIGO stage and lymph node metastasis of CC patients. Function assays showed that SBF2-AS1 inhibition significantly reduced CC cells proliferation both in vitro and in vivo. Mechanistically, we showed that SBF2-AS1 upregulation restrained the activity of miR-361-5p and led to overexpression of FOXM1 in CC cells. Furthermore, we found that miR-361-5p inhibitors could rescue the effects of SBF2-AS1 inhibition on CC cells proliferation. Taken together, we demonstrated that the SBF2-AS1/miR-361-5p/FOXM1 axis might play an important role in CC progression. SBF2-AS1 might serve as a potential therapeutic target for CC treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer-related molecular mechanisms research · Circular RNAs in diseases · RNA modifications and cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Gynecology, Cangzhou Central Hospital

Department of Gynecology, The First Affiliated Hospital of Xinxiang Medical University

References (26)

Show source-provided references
1. 10.3322/caac.2125410.3322/caac.21254 ↗
2. 10.21147/j.issn.1000-9604.2018.01.0110.21147/j.issn.1000-9604.2018.01.01 ↗
3. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Canadian Med Assoc J. 2001;164:1017–1025.
4. 10.1007/978-3-319-45231-9_210.1007/978-3-319-45231-9_2 ↗
5. 10.1038/nrg252110.1038/nrg2521 ↗
6. 10.1038/nrg360610.1038/nrg3606 ↗
7. 10.1016/j.canlet.2013.06.01310.1016/j.canlet.2013.06.013 ↗
8. 10.1016/j.biopha.2016.11.05810.1016/j.biopha.2016.11.058 ↗
9. Zhang D, Sun G, Zhang H, et al. Long non-coding RNA PVT1 facilitates cervical cancer progression through negative modulation of miR-128-3p. Int J Clin Exp Pathol. 2017;10:4522–4529.
10. 10.1016/j.biopha.2018.03.02410.1016/j.biopha.2018.03.024 ↗
11. Zhao QS, Li L, Zhang L, et al. Over-expression of lncRNA SBF2-AS1 is associated with advanced tumor progression and poor prognosis in patients with non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2016;20:3031–3034.
12. 10.1186/s13046-016-0352-910.1186/s13046-016-0352-9 ↗
13. Zhang YT, Li BP, Zhang B, et al. LncRNA SBF2-AS1 promotes hepatocellular carcinoma metastasis by regulating EMT and predicts unfavorable prognosis. Eur Rev Med Pharmacol Sci. 2018;22:6333–6341.
14. Chen R, Xia W, Wang X, et al. Upregulated long non-coding RNA SBF2-AS1 promotes proliferation in esophageal squamous cell carcinoma. Oncol Lett. 2018;15:5071–5080.
15. 10.1016/j.bbagrm.2015.06.01510.1016/j.bbagrm.2015.06.015 ↗
16. 10.4149/neo_2017_40610.4149/neo_2017_406 ↗
17. 10.18632/oncotarget.2351310.18632/oncotarget.23513 ↗
18. 10.1007/s13277-014-2925-610.1007/s13277-014-2925-6 ↗
19. 10.1016/j.biopha.2017.01.01410.1016/j.biopha.2017.01.014 ↗
20. 10.1016/j.ijbiomac.2018.09.17910.1016/j.ijbiomac.2018.09.179 ↗
21. Zhang S, Dong X, Ji T, et al. Long non-coding RNA UCA1 promotes cell progression by acting as a competing endogenous RNA of ATF2 in prostate cancer. Am J Transl Res. 2017;9:366.
22. 10.14348/molcells.2016.230810.14348/molcells.2016.2308 ↗
23. 10.1038/nrc222310.1038/nrc2223 ↗
24. 10.1016/j.bbcan.2006.08.00610.1016/j.bbcan.2006.08.006 ↗
25. 10.3389/fonc.2018.0048310.3389/fonc.2018.00483 ↗
26. Wang L, Lu J, Zhang H, et al. MicroRNA-876-5p inhibits the progression of glioblastoma multiforme by directly targeting Forkhead box M1. Oncol Rep. 2019;41:702–710.